- The HIV market encompasses a wide array of diagnostic tools, antiretroviral therapies (ART), and preventative interventions, playing a pivotal role in managing one of the most pressing global public health challenges. The continued innovation in treatment modalities and early detection tools is shaping a dynamic and responsive healthcare landscape
- The growing demand for HIV-related healthcare services is largely driven by the increasing global incidence of HIV infections, improved access to healthcare, and the expansion of government-sponsored screening and awareness initiatives, particularly in low- and middle-income countries
- North America dominated the human immunodeficiency virus (HIV) market with the largest revenue share of 39% in 2024, characterized by robust healthcare infrastructure, wide availability of advanced therapies, and ongoing R&D efforts aimed at long-acting treatments and vaccine development. The U.S. remains at the forefront, supported by strong public-private partnerships and high treatment adherence rates
- Asia-Pacific is expected to be the fastest growing region in the human immunodeficiency virus (HIV) market during the forecast period due to rising healthcare expenditure, increasing public health initiatives, and expanding awareness programs targeting high-risk populations
- Antibody Test segment dominated the human immunodeficiency virus (HIV) market with a market share of 33.2% in 2024, driven by its widespread availability, affordability, and rapid results, making it the primary choice for initial HIV screening worldwide
